AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Regulation FD Disclosure
Item 7.01.
(d) Exhibits
| 99.1 | Press release issued by the Company on March 25, 2020, furnished herewith. |
AVADEL PHARMACEUTICALS PLC Exhibit
EX-99.1 2 tm2013694d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Avadel Pharmaceuticals Completes the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy – – – Topline data from the REST-ON study expected in Q2 2020 DUBLIN,…
To view the full exhibit click here
